The former describes a method for reducing body weight by administration of the drug once weekly in an amount of at least 0.7 mg and up to 1.6 mg to a subject, while the latter describes its administration in an amount of about 2.4 mg weekly
NUMERO(S) DAUTORISATION DE MISE SUR LE MARCHE 34009 311 363 8 5 : 4 ml en ampoule (verre incolore), bote de 6
Post-treatment side effects
For patients with existing cardiac impairment, weight loss is linked to improved cardiac function and a significant reduction in the incidence of cardiovascular events in the future
Liakos CI, Papadopoulos DP, Sanidas EA, Markou MI, Hatziagelaki EE, Grassos CA, et al
Association of basal forebrain atrophy with cognitive decline in early Alzheimer disease